Ltd. Kck Sells 2,572 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 2,572 shares of NeuroPace stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $6.35, for a total value of $16,332.20. Following the sale, the insider now directly owns 5,525,905 shares in the company, valued at approximately $35,089,496.75. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The stock was sold at an average price of $6.57, for a total value of $45,333.00.
• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The shares were sold at an average price of $6.54, for a total value of $26,362.74.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The stock was sold at an average price of $6.10, for a total value of $19,050.30.
• On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The shares were sold at an average price of $6.66, for a total transaction of $32,700.60.
• On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The stock was sold at an average price of $6.97, for a total transaction of $23,126.46.

NeuroPace Stock Performance

NASDAQ NPCE opened at $6.47 on Friday. The company has a 50 day moving average of $7.05 and a 200-day moving average of $8.38. The company has a current ratio of 6.37, a quick ratio of 5.47 and a debt-to-equity ratio of 5.97. NeuroPace, Inc. has a 1-year low of $5.73 and a 1-year high of $18.15. The firm has a market cap of $186.13 million, a price-to-earnings ratio of -5.44 and a beta of 1.78.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The company had revenue of $19.26 million during the quarter, compared to analyst estimates of $18.30 million. During the same period last year, the company posted ($0.36) earnings per share. The firm’s quarterly revenue was up 16.6% compared to the same quarter last year. On average, equities analysts forecast that NeuroPace, Inc. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NPCE. Morgan Stanley dropped their price target on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a research report on Monday, July 15th. Wells Fargo & Company dropped their target price on NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $18.00 target price on shares of NeuroPace in a research report on Wednesday, August 14th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, NeuroPace presently has an average rating of “Moderate Buy” and a consensus target price of $14.00.

Hedge Funds Weigh In On NeuroPace

A number of large investors have recently modified their holdings of NPCE. Vanguard Group Inc. increased its holdings in shares of NeuroPace by 18.3% in the first quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock valued at $6,450,000 after purchasing an additional 75,512 shares in the last quarter. Acadian Asset Management LLC bought a new position in NeuroPace in the 1st quarter valued at $621,000. Hillsdale Investment Management Inc. acquired a new stake in shares of NeuroPace in the 1st quarter valued at $155,000. Bank of New York Mellon Corp bought a new stake in shares of NeuroPace during the second quarter worth $257,000. Finally, Financial Advocates Investment Management lifted its stake in shares of NeuroPace by 50.0% during the second quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after acquiring an additional 5,000 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.